Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
870 studies found for:    "Mantle cell lymphoma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: lenalidomide;   Biological: rituximab
2 Completed
Has Results
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: modified Hyper-CVAD
3 Completed
Has Results
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone
4 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
5 Terminated
Has Results
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: P276-00
6 Recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
7 Active, not recruiting Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Rituximab, Bendamustine, Cytarabine.
8 Completed Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: MANTLE CELL LYMPHOMA
Intervention: Drug: Lenalidomide and Dexametasone
9 Terminated Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: ZARNESTRA (Tipifarnib)
10 Completed Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
Condition: Mantle Cell Lymphoma
Interventions: Drug: Adriblastin;   Drug: dexamethasone;   Drug: Chlorambucil;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: alkeran;   Procedure: Total body irradiation (8Gy/4fr);   Drug: vincristine
11 Completed Study of Mantle Cell Lymphoma Treatment by RiBVD
Condition: Mantle Cell Lymphoma
Intervention: Drug: RiBVD
12 Completed Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Procedure: Intensive Induction-BMT
13 Completed Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Rituximab;   Drug: Zevalin
14 Active, not recruiting Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Bortezomib;   Drug: Lenalidomide
15 Completed Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Condition: Mantle Cell Lymphoma
Intervention: Drug: Y-90 Ibritumomab tiuxetan
16 Completed A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
17 Active, not recruiting Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Condition: Mantle Cell Lymphoma
Intervention: Drug: lenalidomide, bendamustine, rituximab
18 Active, not recruiting Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Temsirolimus
19 Unknown  Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma Recurrent
Intervention: Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide
20 Withdrawn A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: acalabrutinib;   Drug: ibrutinib;   Drug: rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.